Insights from AAPS PharmSci 360 Live with Dr. Mark Arnold

https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/45/36/06/4536062b-537f-9acf-2c9e-25a5fd08fc82/mza_7029884595797663501.jpg/600x600bb.jpg

BioTalk Unzipped

38 episodes

2 weeks ago

Gregory Austin and Dr. Chad Briscoe unzip, unlock, and uncover, the Stories Behind Medical Progress by sharing the latest and greatest advances in biopharmaceuticals and medical technologies in a fun, entertaining, and enlightening interview format. We bring on innovative leaders across the life sciences. The format is like a conversation you might overhear at the bar or at dinner after a day of great life science talks at a conference, engaging and accessible.

All content for BioTalk Unzipped is the property of BioTalk Unzipped and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Insights from AAPS PharmSci 360 Live with Dr. Mark Arnold

BioTalk Unzipped

29 minutes 49 seconds

10 months ago

Insights from AAPS PharmSci 360 Live with Dr. Mark Arnold

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.

Chapters

00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360

03:45 Samaritan's Purse Charity and Community Impact

05:16 Most impactful talk at AAPS?

11:50 Comparative Analysis of FDA and EU Regulations

17:37 The Drive Behind Bioanalytical Work

22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis

Takeaways

The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials.
Community support through charities like Samaritan's Purse is crucial during crises.
The importance of collaboration in advancing drug development and bioanalytical methods.
Innovations in RNA editing present new bioanalytical challenges.
The drive to help patients is a key motivator for professionals in the field.

Sound Bites

"I worked on that drug and there's a clear benefit."
"It's getting that new therapy to a patient."
"This is going to change and potentially delay biomarkers."

New News Story:

Wave sees RNA editing validation in early trial results

◦https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/

How to reach us:

Please donate to: Samaritan’s Purse

https://www.samaritanspurse.org/

Mark Arnold

https://www.linkedin.com/in/markearnoldphd/

Blog - https://bioanalysisandbiomarkers.blogspot.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Celerion - https://www.celerion.com/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

ECI - https://eci-rx.com /

Image Credits

AAPS